Background: Antibody microarrays (Ab-array) represent a new, innovative proteomics platform for high-throughput protein expression profi ling in body fl uids. Because they allow for multiplexed measurements in small sample volumes, Ab-arrays are an interesting alternative to conventional indirect sandwich immunoassay (ELISA or DELFIA) tests in clinical or population screening if sets of markers are to be analyzed simultaneously. However, to allow implementation of Ab-arrays in clinical or population screening programs, it is of vital importance to establish that this method is both sensitive and quantitative. Methods: This study developed and optimized a duplex Ab-array for pregnancy-associated plasma protein A (PAPP-A) and human chorion gonadotropin (f β -hCG), two serum biomarkers currently analyzed by conventional biochemical techniques in prenatal screening. Serum samples from pregnant women, representing the dynamic range of both markers, were analyzed on Ab-arrays, and validated to the, in prenatal screening routinely applied, AutoDelfi a system. Results: Two different array hybridization conditions were tested, i.e., direct and indirect labeling, of which the indirect method displayed a sensitive and quantitative performance and a low intra-and inter-assay variation. Conclusions: Taken together, these fi ndings indicate that Ab-array technology is a promising alternative for ELISA or DELFIA in population screening programs, allowing future quantitative analysis of multiple biomarkers simultaneously in small volumes of serum.
Introduction
Screening for Down syndrome in the fi rst trimester of pregnancy is based on the maternal serum parameters pregnancy-associated plasma protein A (PAPP-A) and the free beta-subunit of human chorion gonadotropin (f β -hCG) combined with ultrasonographic nuchal translucency measurement (NT) of the fetus and maternal age. A risk calculation based on these three markers together with maternal age provides a 75 % -85 % detection rate of all Down syndrome cases at an approximately 5 % false-positive rate (1 -3) . To improve these rates, several research groups are putting efforts into additional biomarker discovery using proteomics techniques (4 -7) . The ultimate goal is the development of a multi-marker prenatal screening test for Down syndrome. Multi-marker tests are envisioned to be essential for population-screening settings to detect prenatal conditions as well as several diseases (e.g., cancer, cardiovascular diseases), since they provide higher sensitivity and specifi city than single marker tests (8) .
The current prenatal screening test for trisomies is performed using dissociation-enhanced lanthanide fl uorescent immunoassay (DELFIA), an immunoassay based on timeresolved fl uorometric performed in well plates. Traditional ELISA and DELFIA are the gold standard for quantitative protein measurement in serum and can be performed rapidly for a large number of samples. However, these methods are less suitable to analyze large marker sets simultaneously in a high-throughput manner in small sample volumes. For this, antibody microarrays (Ab-arrays) could provide a useful alternative for population-screening purposes. Ab-arrays are a high-throughput platform for protein expression profi ling, allowing parallel detection of many markers, with high sensitivity. Furthermore, Ab-arrays are interesting in the screening fi eld since they allow for large-scale use and only require fi nger-prick amounts of blood (approx. 10 μ L suffi ces). Ab-arrays are already increasingly used in biomarker discovery studies (9) . Currently, several array-immobilization and detection technologies are available (10, 11) and the number of commercially available antibodies is increasing. Due to these developments, future potential to generate multi-marker tests based on Ab-array technology becomes feasible.
For prenatal-screening, good quantitative performance of the test is an important prerequisite for potential future use to allow incorporation in the risk calculation algorithm. Ab-arrays are increasingly used in biomarker discovery; however quantitative validation studies comprising Ab-array comparison with conventional immunoassays (ELISA or DELFIA) are scarce (10, 12, 13) . For our study, we designed duplex Ab-arrays consisting of current prenatal screening markers (PAPP-A and f β -hCG) and analyzed quantitative performance of two different Ab-array methods ( Figure 1 ). (i) The direct method, where serum samples are directly labeled with fl uorescent dyes and captured with a capture antibody spotted on the array; and (ii) the indirect or sandwich method, a label-free method requiring two antibodies for the same antigen, where samples are captured with a capture antibody spotted on the array and subsequently detected with a labeled detection antibody. The aims of this study were to (1) develop and optimize two different Ab-array methods, (2) compare Ab-array performance with the conventional AutoDelfi a method and (3) evaluate quantitative performance and sensitivity of the duplex Ab-arrays on a set of serum samples, derived from pregnant women representing the occurring concentration range of the two current biochemical screening markers. In addition to serum samples from the serum bank, commercial human serum (Cambrex Corporation, East Rutherford, NJ, USA) was used to optimize conditions.
Materials and methods

Serum samples, standards and antibodies
Antibody array production
Capture antibodies for PAPP-A, f β -hCG, Cy3/Cy5 and IgG and bovine serum albumin (BSA) were diluted in 2 × Protein Array Buffer (Whatman, Kent, UK) to a concentration of 0.1 -2.0 mg/mL. Antibodies were spotted on 16-array nitrocellulose FAST-slides (Whatman) using a Piezorray Non-contact Microarraying System (PerkinElmer, Wellesley, MA, USA). Two drops per position, about 330 pL/drop, were spotted under humidity < 40 % . Four replicates of each antibody were arrayed to ensure adequate statistics. The slides were stored in a desiccator cabinet (Nalgene, Rochester, NY, USA).
Antibody array hybridization
Blocking and hybridization conditions Anti-Cy3/Cy5 and anti-human IgG were spotted at the Array as positive controls and BSA was spotted as a negative control (controls aimed at detecting possible non-specifi c binding). Slides were mounted in the FAST-frame set-up (Whatman), generating 16 independent wells. Blocking and incubation conditions consisted of overnight (16 h) blocking at room temperature in 100 μ L Protein Array Blocking Buffer (Whatman), and incubation and washing steps using 90 μ L Sigma Washing Buffer (Sigma-Aldrich) per well for both methods.
Serum labeling and incubation using the direct Ab-array method Serum protein concentrations were determined using a BCA Protein Assay Reagent Kit (Pierce, Rockford, IL, USA). Cy-dye labeling of serum was performed according to the manufacturer ' s protocol (GE Healthcare, Piscataway, NJ, USA). In short, approximately 10 μ L serum was diluted in conjugation buffer to a concentration of 1 mg/mL protein extract and labeled with Cy5 mono-reactive dye using NHS-ester amine residue labeling. Unreacted dye was removed through SigmaSpin Post-Reaction Clean-up Columns (Sigma-Aldrich). The degree of labeling was determined by the Dye-to-Protein Molar ratio (D/P ratio) using a NanoDrop ND-1000 (Thermo Scientifi c) and were 3.70 ( ± 1.09). All D/P ratios were above 2, indicative of the average number of fl uorophores on a labeled protein.
Next, 90 μ L of the labeled samples in Sigma Washing Buffer (PBS, pH 7.4, 0.05 % Tween) were added in a range of dilutions (1:100 -1:500) and slides were incubated for 30 min at room temperature. Slides were rinsed three times for 5 min with Washing Buffer, once with deionised water and dried by vacuum.
Incubation indirect method
Small serum volumes (9 -45 μ L) were diluted ranging from 1:2 to 1:10. Arrays were incubated with 90 μ L diluted serum samples or pooled PAPP-A and f β -hCG standards for 1 h at room temperature. Arrays were washed in Sigma washing buffer three times for 5 min and incubated with biotinylated PAPP-A and f β -hCG antibodies in a range of dilutions (1:50 -1:2000) for 1 h at room temperature. Subsequently, slides were washed three times for 5 min and incubated with StreptavidinDylight649 (diluted 500 times according to manufacturer; Jackson ImmunoResearch Laboratories, West Grove, PA, USA) for 30 min at room temperature. Finally, slides were rinsed three times for 5 min with washing buffer, once with deionised water and dried by vacuum.
Data extraction, data analysis and statistical analysis
Slides were scanned with a Confocal Microarray Scanner (PerkinElmer) at 10 μ m resolution. ScanArray Express software V4.0 (PerkinElmer) was used to quantify spot intensity using the adaptive circle method. Corrected median intensity values for each spot (median intensity minus local median background) were exported into Microsoft Excel for further analysis. Median intensity values of the four replicate spots were calculated. To assess the assay signal quality, signal-to-background levels between different conditions were compared. Furthermore, the dynamic range of different PAPP-A and f β -hCG standards and serum and coeffi cients of variation (CV) (Prism 4, GraphPad software Inc., San Diego, CA, USA) were calculated and compared. For the indirect method, the reproducibility between arrays, slides and batches was calculated using Pearson ' s correlation and CV-values. Calculation from array signal intensity to serum concentrations were performed using a calibration curve fi tted to signal intensities obtained with PAPP-A and f β -hCG protein standards (AutoDelfi a). Parameter fi tting was performed with the statistical program " R " ( www.R-project.org ) (14) , based on the parameter
.
AutoDelfi a
As a reference assay, PAPP-A and f β -hCG immunoassays (both PerkinElmer) were used to determine PAPP-A and f β -hCG concentrations. These immunoassays are commercially available and based on the original report by Qin et al. (16) .
Results
Development and optimisation of the antibody array PAPP-A and f β -hCG assays
To obtain functional Ab-array assays for the current prenatal screening markers PAPP-A and f β -hCG, a variety of general array spotting and labeling methods and materials were optimized for both the direct and indirect Ab-array platform (data not shown). Conditions are described in the material and methods section.
Antibody and serum titration
To allow sensitive and quantitative detection, the optimal spot concentrations for the capture-antibodies of the two current screening markers PAPP-A and f β -hCG and optimal serum dilutions were determined. Different spot-concentrations for Cy3/Cy5 and human IgG antibodies were included in the analysis as positive controls. Quantitative detection requires optimal capture of antigens from standards or serum (17) . Therefore, the capture antibody concentration at which the maximum spot signal appeared, using commercial human serum, was determined for quantitative performance of the arrays. Optimal spotted capture-antibody concentration was 1 mg/mL for anti-PAPP-A, 0.5 mg/mL for anti-f β -hCG and anti-IgG and 0.1 mg/mL for anti-Cy3/Cy5. Optimal serum dilution, for both the direct and indirect Ab-array method, were defi ned as the dilution where the analyte concentration was linearly correlated with the intensity of the signal combined with lowest CV between the four identical spots. For the direct labeling method, a 1:250 labeled serum dilution provided the best results. For the indirect method a 1:10 dilution of serum gave optimal results for both PAPP-A and f β -hCG. This was based on linearity of concentrations vs. intensity signal, low CV and the option to use one serum dilution for both markers, a prerequisite for combined use in a multiplex platform.
To determine the optimal detection-antibody concentration, we tested several detection-antibody dilutions for consistent performance over the dynamic range of both PAPP-A and f β -hCG serum concentrations. For the detection-antibodies, the optimal dilution factors were 1:100 for PAPP-A and 1:250 for f β -hCG. For the Streptavidin-Dylight649 the manufacturer ' s recommendation of 1:500 dilution gave optimal results.
Quantitative performance of the antibody array
Quantitative performance of both Ab-array methods was assessed using three clinically relevant low, intermediate and high serum levels of PAPP-A. The indirect labeling method showed good quantitative performance in that signal intensity increased with known, increasing PAPP-A concentrations in serum (Figure 2 ). The direct method showed presence of the proteins, but failed to refl ect quantitative levels for both proteins (f β -hCG, Supplemental data, Figure 1 ). For prenatal screening quantitative performance is required, therefore the indirect array method was used for follow-up studies on reproducibility and dynamic range.
Reproducibility of the indirect antibody array method
To evaluate assay reproducibility, serum samples were hybridized onto different arrays and different slides obtained from different spot batches. The reproducibility was evaluated by calculating the intra-assay variation, which includes variations consisting of CV ' s from arrays on one slide and inter-assay variations consisting of CV ' s from arrays on different slides ( Table 1 ) . As expected the reproducibility of the intra-assay was highest. Intra-assay precision using serum was below 8 % for PAPP-A in the range 178 -8219 mU/L and below 11 % for f β -hCG in the range 9.5 -193.4 μ g/L (Figure 3 ). Overall the reproducibility of different slides and spot-batches was also high; since CVs were below 15 % , a criterion for FDA approved tests (18) . Accurate performance of serum concentrations of PAPP-A and f β -hCG was assessed by repeated analysis on different slides, showing high correlation coeffi cient between arrays and slides ( > 0.998; Figure 4 ) . Within three different spot batches correlation coeffi cients were at least 0.9740 for both proteins.
Assessment of the dynamic range of the indirect antibody array
Potential applicability of Ab-arrays in screening setting depends on the quantitative performance over the entire clinical range of PAPP-A and f β -hCG concentrations, i.e., concentrations routinely detected in sera from pregnant women. To test whether the indirect Ab-arrays allowed detection of these clinical concentrations, sera with PAPP-A and f β -hCG concentrations from the lower 1 % CI to the upper 1 % CI values of occurring AutoDelfi a concentrations in the Dutch screening population were selected. Quantitative performance was assessed using both recombinant protein standards and human serum samples from the screening in a monoplex array setting. Standards for both markers in concentrations covering the expected ranges in maternal serum from 0 to 10,000 mU/L for PAPP-A and 0 -200 μ g/L for f β -hCG showed linear detection with correlation coeffi cients of r = 0.978 for both PAPP-A and f β -hCG ( Figure 5 , black dots). Ab-array analysis of maternal serum samples showed high correlations for both proteins of r = 0.985 for PAPP-A and r = 0.995 for f β -hCG with concentrations derived from the current AutoDelfi a assay ( Figure 6 , black dots).
Serum analysis on a duplex array
To evaluate the potential of duplex analyses of PAPP-A and f β -hCG, the indirect Ab-array was tested using a combination of the two markers within one array. A cocktail of detection antibodies showed negligible cross-reaction. As shown in Figure 5 the combined assay provided, for standards over the entire dynamic range of clinical concentrations, similar results compared to separate monoplex assays. Maternal sera from the fi rst trimester screening population were analyzed on the duplex array reaching adequate quantitative performance similar to the monoplex assay ( Figures 5 and 6 , gray triangles). Moreover, duplex analysis of maternal serum samples showed excellent correlations of r = 0.962 for PAPP-A and r = 0.999 for f β -hCG, with concentrations derived from the current AutoDelfi a assays for each single analyte.
Discussion
Antibody microarray technology can be useful for the largescale parallel analysis of multiple markers in small sample volumes. The number of studies describing the use of Ab-arrays is increasing fast, and results from these studies have already shown different potential applications for Ab-arrays in human disease detection, such as cancer detection in serum or other body fl uids (11, 19) . Ab-arrays can very well be put to use in population screening settings, in which often several biomarkers are to be analyzed. An example of such a population screening setting is the prenatal screening for trisomies in the fi rst trimester of pregnancy. This screening is currently widely applied; however, sensitivity and specifi city can be improved upon by the addition of biochemical markers to the current screening test. However, obviously, when more markers are to be added to the screening test, standard DELFIA methods, which can only be used for single or dual marker analysis, are no longer the obvious choice. Here, we successfully explored the potential of Ab-array technology for prenatal screening for trisomies, since this technology allows extending the number of biomarkers to be analyzed relatively easily.
Given that the risk calculation for trisomy screening requires precise marker concentrations, the applicability of an Ab-array highly depends on its quantitative performance. So far, however, the quantitative performance of Ab-arrays in direct comparison with ELISA-or DELFIA-based method has not been studied extensively (10, 12, 13) .
The aim of the present study was to evaluate quantitative performance of duplex Ab-arrays that allow for parallel assessment of the current prenatal screening markers for trisomies, PAPP-A and f β -hCG, in small sample volumes. We hypothesized that if the two current screening markers could be determined in a quantitative manner, this technique would be the obvious choice to extend the current screening with more, sensitive markers. To accomplish the evaluation, we focused on the development, performance and quality of two different Ab-array methods (direct and indirect) for the quantitative profi ling of human serum markers.
The direct method showed the presence of both PAPP-A and f β -hCG in serum, but failed to refl ect linear performance. An explanation for the non-quantitative performance of the direct method could be the labeling of whole serum, there are concerns that the rather large size of the dyes infl uences the antibody-antigen binding due to steric hindrance (20) .
Another explanation is variation due to labeling. Labeling effi ciency between proteins differs due to the fact that serum proteins do not all have easily accessible amines for NHSactivated dye labeling at lysine residues (10, 20, 21) . The direct method is successfully used in biomarker discovery studies where present vs. absent data or semi-quantitative information on analytes fulfi l the need (22) . The advantage of the direct method in biomarker discovery is the possibility to expand an Ab-array up to thousands of antibodies. Detection of multiple proteins with an indirect Ab-array requires a cocktail of detection antibodies, limiting the number of markers to approximately 10 -30 that can be analyzed simultaneously. This is partly due to increased possibility of cross-reactivity, but also because antibodies need to be applicable in the same serum dilution range. However, for screening settings this amount of 10 -30 markers is expected to be enough to reach the desired test sensitivity. The indirect method showed good qualitative and quantitative performance for both markers. The variation between arrays, slides and batches was within FDA-set values (18) and automation of assay execution is expected to bring the variation down to levels comparable to current automated test systems which are 5 % -6 % given by the UK National External Quality Assessment Service (UKNEQAS).
Our aim was to develop a duplex Ab-array to quantitatively determine levels of PAPP-A and f β -hCG simultaneously in serum of pregnant women participating in the prenatal screening program. Serum analysis from pregnant women from our serum bank allowed the selection of the full dynamic range of current screening-markers PAPP-A and f β -hCG and could, therefore, be used to validate our Ab-array for prenatal trisomy screening purposes. The dynamic range of our indirect Ab-Array appeared linear over the occurring concentrations of both PAPP-A and f β -hCG, ranging from the 1st percentile to the 99th percentile serum concentrations available in our serum bank. Furthermore, the indirect Ab-array method showed high correlation with the current standard method AutoDelfi a for both markers. Therefore, this duplex, indirect method fulfi ls all requirements to be incorporated in a screening setting.
The possibility of duplex analysis of the current markers, and in the future possibly multiplex analysis with additional markers, is a great advantage of the Ab-array technology. In addition to this, the Ab-array method is a sensitive method allowing both PAPP-A and f β -hCG to be measured in the same 10-fold serum dilution with adequate performance over the entire dynamic range. In the current AutoDelfi a assay, serum dilutions used to assess PAPP-A and f β -hCG levels are 5-fold for PAPP-A and non-diluted for f β -hCG. The high sensitivity of the Ab-array method could be explained by either the dense spotted capture-antibody compared to the density in indirect sandwich immunoassay wells (23) , or it could be due to the optimal fl uorescent signal by the use of the Dylight-649 dye.
Highly interesting for future application in a screening setting, is that a small serum volume of 10 μ L was suffi cient for Ab-array-based analyses. This volume is independent of the number of markers present on the array. So, up to 30 markers can be analyzed simultaneously in only 10 μ L serum. As a comparison, each ELISA or DELFIA method requires 10 -25 μ L per single analyte. Consequently, Ab-arrays allow for collection of blood through a fi ngerprick, whereas ELISA-or DELFIA-based screening assays require venous blood sampling. Therefore, interestingly, Ab-arrays open up the possibility to implement this test in a home-setting where women collect fi ngerprick blood themselves and, next, send their blood sample to the screening laboratory. Fingerprick blood can be sampled using small tubes; however, using dried bloodspots on fi lter paper as currently applied in the Dutch neonatal screening program, providing for very low degradation of proteins, would be even more feasible. In addition to simplifying the practical aspects of the prenatal trisomy screening, applying Ab-array technology would also allow the development of a broader prenatal screening assay. Potential markers to increase detection of trisomies could be added to a multiplex Ab-array in the future (24 -26) . Overall, the prenatal screening would be less invasive for pregnant women and the Figure 6 Concentrations of PAPP-A (A) and f β -hCG (B) identifi ed using monoplex (black dots) and multiplex (gray triangles) indirect antibody arrays. In the multiplex arrays, a cocktail of α -PAPP-A and α -f β -hCG antibodies was used as the detection antibody mixture. Antibody array concentrations were calculated using standard curves on the same platform; values were plotted against observed AutoDelfi a concentrations. logistic procedures of the screening would be highly simplifi ed if blood can be drawn via fi ngerprick carried out outside the clinical laboratory. However, one has to keep in mind that, before the indirect Ab-array method can be incorporated, further automation is required to meet the UKNEQAS standards for screening programs. Moreover validation on large study cohorts are required.
Conclusions
In this study we showed that currently-used maternal serum markers (PAPP-A and f β -hCG) in prenatal trisomy screening can be quantitatively detected jointly within one assay using small amounts (approx. 10 μ L) of serum using duplex Ab-arrays. This now opens possibilities to (i) extend the duplex Ab-array to a multiplex array with new markers to improve the performance of the prenatal trisomy screening test, since the detection rate of the currently used test is rather low; (ii) make the screening applicable to the home setting; and (iii) extend the prenatal screening to other syndromes. For all these potential applications we are currently performing experiments to include newly identifi ed, promising markers in the platform to improve the detection rate of Down syndrome, to discover and include markers detecting other trisomy pregnancies (5) , and to test the performance of blood-dried bloodspots.
